Logo image of TEM

TEMPUS AI INC (TEM) Stock Fundamental Analysis

NASDAQ:TEM - Nasdaq - US88023B1035 - Common Stock - Currency: USD

60.97  +1.79 (+3.02%)

After market: 60.55 -0.42 (-0.69%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TEM. TEM was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of TEM have multiple concerns. TEM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TEM has reported negative net income.
TEM had a negative operating cash flow in the past year.
In the past 5 years TEM always reported negative net income.
TEM had a negative operating cash flow in each of the past 5 years.
TEM Yearly Net Income VS EBIT VS OCF VS FCFTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

TEM has a worse Return On Assets (-46.74%) than 81.82% of its industry peers.
The Return On Equity of TEM (-221.13%) is worse than 85.45% of its industry peers.
Industry RankSector Rank
ROA -46.74%
ROE -221.13%
ROIC N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TEM Yearly ROA, ROE, ROICTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

TEM has a Gross Margin of 57.09%. This is in the better half of the industry: TEM outperforms 72.73% of its industry peers.
TEM's Gross Margin has improved in the last couple of years.
TEM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.09%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
TEM Yearly Profit, Operating, Gross MarginsTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

3

2. Health

2.1 Basic Checks

TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TEM has less shares outstanding
TEM has less shares outstanding than it did 5 years ago.
TEM has a better debt/assets ratio than last year.
TEM Yearly Shares OutstandingTEM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
TEM Yearly Total Debt VS Total AssetsTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 2.39 indicates that TEM is not a great score, but indicates only limited risk for bankruptcy at the moment.
TEM has a Altman-Z score of 2.39. This is comparable to the rest of the industry: TEM outperforms 54.55% of its industry peers.
A Debt/Equity ratio of 2.45 is on the high side and indicates that TEM has dependencies on debt financing.
The Debt to Equity ratio of TEM (2.45) is worse than 85.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.45
Debt/FCF N/A
Altman-Z 2.39
ROIC/WACCN/A
WACC10.09%
TEM Yearly LT Debt VS Equity VS FCFTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 1.71 indicates that TEM should not have too much problems paying its short term obligations.
The Current ratio of TEM (1.71) is worse than 67.27% of its industry peers.
A Quick Ratio of 1.56 indicates that TEM should not have too much problems paying its short term obligations.
TEM has a worse Quick ratio (1.56) than 60.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.56
TEM Yearly Current Assets VS Current LiabilitesTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

TEM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -338.03%.
The Revenue has grown by 42.93% in the past year. This is a very strong growth!
The Revenue has been growing by 62.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-338.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.67%
Revenue 1Y (TTM)42.93%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%75.38%

3.2 Future

The Earnings Per Share is expected to grow by 30.40% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 40.54% on average over the next years. This is a very strong growth
EPS Next Y70.81%
EPS Next 2Y38.22%
EPS Next 3Y30.4%
EPS Next 5YN/A
Revenue Next Year79.02%
Revenue Next 2Y49.51%
Revenue Next 3Y40.54%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TEM Yearly Revenue VS EstimatesTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
TEM Yearly EPS VS EstimatesTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TEM Price Earnings VS Forward Price EarningsTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TEM Per share dataTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

TEM's earnings are expected to grow with 30.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.22%
EPS Next 3Y30.4%

More info and screens

0

5. Dividend

5.1 Amount

TEM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPUS AI INC

NASDAQ:TEM (7/3/2025, 8:12:17 PM)

After market: 60.55 -0.42 (-0.69%)

60.97

+1.79 (+3.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04
Inst Owners37.63%
Inst Owner Change18.18%
Ins Owners4.39%
Ins Owner Change-9.39%
Market Cap10.56B
Analysts75
Price Target68 (11.53%)
Short Float %20.67%
Short Ratio1.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.25%
Min EPS beat(2)11.05%
Max EPS beat(2)11.44%
EPS beat(4)4
Avg EPS beat(4)23.67%
Min EPS beat(4)11.05%
Max EPS beat(4)52.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.07%
Min Revenue beat(2)-2.18%
Max Revenue beat(2)2.05%
Revenue beat(4)2
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-2.18%
Max Revenue beat(4)2.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.33%
PT rev (3m)1.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-34.43%
EPS NY rev (1m)-3.72%
EPS NY rev (3m)-2.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.53%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.14
P/FCF N/A
P/OCF N/A
P/B 32.36
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.12
OCFYN/A
SpS4.64
BVpS1.88
TBVpS-2.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.74%
ROE -221.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.09%
FCFM N/A
ROA(3y)-60.21%
ROA(5y)-54.09%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y19.22%
GM growth 5Y16.28%
F-Score5
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 2.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.04%
Cap/Sales 2.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.56
Altman-Z 2.39
F-Score5
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)74.55%
Cap/Depr(5y)66.22%
Cap/Sales(3y)5.14%
Cap/Sales(5y)5.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-338.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.67%
EPS Next Y70.81%
EPS Next 2Y38.22%
EPS Next 3Y30.4%
EPS Next 5YN/A
Revenue 1Y (TTM)42.93%
Revenue growth 3Y39.06%
Revenue growth 5Y62.05%
Sales Q2Q%75.38%
Revenue Next Year79.02%
Revenue Next 2Y49.51%
Revenue Next 3Y40.54%
Revenue Next 5YN/A
EBIT growth 1Y-261.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year104.66%
EBIT Next 3Y46.34%
EBIT Next 5YN/A
FCF growth 1Y15.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.8%
OCF growth 3YN/A
OCF growth 5YN/A